-
Mashup Score: 5Homepage | Lupus Science & Medicine - 1 month(s) ago
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5Homepage | Lupus Science & Medicine - 2 month(s) ago
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Find the latest content at LSM #SLE #Lupus #Autoimmunity #Rheumatology #Research #Data #Patients https://t.co/jAGbEgwqzx
-
-
Mashup Score: 5Homepage | Lupus Science & Medicine - 2 month(s) ago
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Find the latest content at LSM #SLE #Lupus #Autoimmunity #Rheumatology #Research #Data #Patients https://t.co/jAGbEgwqzx
-
-
Mashup Score: 6Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway - 3 month(s) ago
Objective Lupus nephritis (LN) is a major complication and cause of death among patients with SLE. This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin in kidney injury from LN-induced inflammation. Methods In vivo study, 8-week-old MRL/MpJ-Faslpr/J (MRL/lpr) mice were randomly divided into two groups (n=12 each): daily administration of 0.3 mg/mL metformin in drinking water and control (water only). Body weight and urinary samples were measured biweekly. Mice were sacrificed after 8-week treatment to harvest serum, lymph nodes, spleen and kidneys. In vitro study, human kidney-2 (HK-2) cells were pretreated with 1 mM metformin for 1 hour and then stimulated with 20 µg/mL lipopolysaccharides (LPS) or 10 ng/mL tumour necrosis factor-α (TNF-α) for another 48 hours. Protein was collected for subsequent analysis. Results We found that metformin administration improved renal function in MRL/lpr lupus-prone mice, measured by decreased urea nitr
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Conclusions: Metformin alleviated kidney injury in LN. Read the full study here: https://t.co/b4re9zYqIG #Lupus #ACR24 #MedicalResearch
-
-
Mashup Score: 2Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis - 3 month(s) ago
Objective Recent studies reported that SLE is characterised by altered interactions between the microbiome and immune system. We performed a meta-analysis of publications on this topic. Methods Case–control studies that compared patients with SLE and healthy controls (HCs) and determined the diversity of the gut microbiota and the abundance of different microbes were examined. Stata/MP V.16 was used for the meta-analysis. A Bonferroni correction for multiple tests was used to reduce the likelihood of false-positive results. Results We included 11 case–control studies that examined 373 patients with SLE and 1288 HCs. These studies were performed in five countries and nine cities. Compared with HCs, patients with SLE had gut microbiota with lower Shannon-Wiener diversity index (weighted mean difference=−0.22, 95% CI −0.32 to –0.13, p<0.001) and lower Chao1 richness (standardised mean difference (SMD)=−0.62, 95% CI −1.04 to –0.21, p=0.003). Patients with SLE had lower abundance of Ruminoc
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
At #ACR24? You may be interested to discover the association between SLE and gut microbiota disruptions in this extensive meta-analysis- https://t.co/Mti8W96Cdc #LupusResearch
-
-
Mashup Score: 1Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria - 3 month(s) ago
Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE. We reviewed established definitions of disease modification in other conditions and identified a meaningful effect on ‘disease manifestations’ (ie, signs, symptoms and patient-reported outcomes) and on ‘disease outcomes’ (eg, long-term remission or progression of damage) as the key principles of disease modification, indicating a positive effect on the natural course of the disease. Based on these findings and the treatment goals and outcome measures for SLE, including lupus nephritis, we suggest a definition of disease modification based on disease activity indices and organ damage outcomes, with the latter as a key anchor. A set of evaluation criteria is also suggested. Establishing a definition of disease modification in SLE will clarify which treatments can be considered disease modifying, provide an opportunity to h
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition exists for SLE. Access our framework here — a must-read for researchers in SLE. Full text: https://t.co/IM9KI01Uxz #ACR24
-
-
Mashup Score: 12Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus - 7 month(s) ago
Objective To determine whether intercurrent infections are a risk factor for subsequent disease flares in systemic lupus erythematosus (SLE). Methods Demographic and clinical characteristics of 203 patients with SLE participating in the Amsterdam SLE cohort were collected at baseline and during follow-up. Collection of data on infections and SLE flares was registry-based and infections and flares were categorised as minor or major, based on predefined criteria. Proportional hazard models with recurrent events and time-varying covariates were used to estimate the HR of SLE flares. Results The incidence rates of major and minor infections were 5.3 per 100 patient years and 63.9 per 100 patient years, respectively. The incidence rates of flares were 3.6 and 15.1 per 100 patient years for major flares and minor flares, respectively. In the proportional hazard model, intercurrent infections (major and minor combined) were associated with the occurrence of SLE flares (major and minor combine
Source: lupus.bmj.comCategories: General Medicine News, General HCPsTweet-
Intercurrent infections may be assoc w/ SLE flares. 203 Amsterdam SLE pts, incidence of major & minor infections were 5.3 & 64/100Pys. Intercurrent infections (major & minor) were assoc w/ SLE flares (HR 1.9); major infx lead to major SLE flares (HR 7.4) https://t.co/DSPgi9KrwT https://t.co/FI7ZYf3CPl
-
-
Mashup Score: 1
Objectives Type 1 interferon (IFN) is key to the pathogenesis of SLE, evidenced by the expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial ISG assessment remains unknown. With the emergence of IFN-blocking drugs, we aimed to examine IFN status in relation to clinical findings longitudinally to provide insights into the value of testing ISG levels over time. Methods Clinical data and whole blood were collected prospectively on adult patients with SLE from a single tertiary lupus centre. IFN status was measured using a panel of ISGs. Findings 729 samples were analysed from 205 patients. At baseline, 62.9% of patients were IFN high, 30.2% IFN low and 6.8% borderline. 142 patients had multiple samples collected, and 87.3% of these demonstrated stable ISG status over time. In longitudinal follow-up, IFN high patients had higher activity in multiple organ domains and spent less time in Lupus Low Disease Activity State, but IFN score did not correlat
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Our Editor in Chief has selected their favourite article from our journal. Check it out: https://t.co/7vW1jK5QKN "Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis" #EULAR2024
-
-
Mashup Score: 1
Objectives Type 1 interferon (IFN) is key to the pathogenesis of SLE, evidenced by the expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial ISG assessment remains unknown. With the emergence of IFN-blocking drugs, we aimed to examine IFN status in relation to clinical findings longitudinally to provide insights into the value of testing ISG levels over time. Methods Clinical data and whole blood were collected prospectively on adult patients with SLE from a single tertiary lupus centre. IFN status was measured using a panel of ISGs. Findings 729 samples were analysed from 205 patients. At baseline, 62.9% of patients were IFN high, 30.2% IFN low and 6.8% borderline. 142 patients had multiple samples collected, and 87.3% of these demonstrated stable ISG status over time. In longitudinal follow-up, IFN high patients had higher activity in multiple organ domains and spent less time in Lupus Low Disease Activity State, but IFN score did not correlat
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Our Editor in Chief has selected their favourite article from our journal. Check it out: https://t.co/7vW1jK5QKN "Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis" #EULAR2024
-
-
Mashup Score: 5Homepage | Lupus Science & Medicine - 9 month(s) ago
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
Source: lupus.bmj.comCategories: General Medicine News, RheumatologyTweet-
Find the latest content at LSM #SLE #Lupus #Autoimmunity #Rheumatology #Research #Data #Patients https://t.co/jAGbEgwqzx
-
Find the latest content at LSM #SLE #Lupus #Autoimmunity #Rheumatology #Research #Data #Patients https://t.co/jAGbEgwqzx